Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
|Articles|December 1, 1996
The American Journal of Managed Care
- November/December 1996
- Volume 2
- Issue 11
Disease Management: Has Anyone Managed to Make It Work?
Author(s)Joseph J. Hreben, MPA
Advertisement
Articles in this issue
almost 30 years ago
The Year in Reviewalmost 30 years ago
Childhood Immunizations: Beyond HEDISalmost 30 years ago
Implementation of a Clinical Pathway for Cesarean Sectionalmost 30 years ago
Six HMOs in Search of a Study: Comments on Two Papers by Horn et alalmost 30 years ago
The Economic and Health-Related Quality of Life Impact of Epilepsyalmost 30 years ago
Telecomputing as a Tool to Increase Consumer Participation in Managed CareAdvertisement
Related to this article
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
Keynote Address Tackles AI’s Role in Health Care, Eye Care
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
5 Things to Know if Retatrutide Is Classified as a Biologic
5